SciNeuro Pharmaceuticals
Rockville, US · Founded 2020 · 33 employees on LinkedIn · 4 known investors
SciNeuro develops targeted therapeutics for neurodegenerative and age-related brain diseases by integrating patient genetics, health history, and advanced diagnostic tools. The company collaborates with scientific institutions to create disease-modifying therapies addressing aging populations' neurological challenges.
Also known as SciNeuro · SciNeuro Pharmaceuticals
Founders & leadership
Investors · 4
Also in the syndicate · 3
Company profile
researched Aug 2026SciNeuro Pharmaceuticals is a clinical-stage biotechnology company developing therapies for neurodegenerative and other central nervous system (CNS) diseases. Founded in 2020, the company has assembled a pipeline spanning discovery through clinical development that is organized around three disease-driving mechanisms of neurodegeneration: neurovascular inflammation, proteinopathy, and immune response. Its stated aim is disease-modifying treatment options for Alzheimer's disease, Parkinson's disease and other CNS disorders.
Disclosed pipeline programs include SNP837, a modular blood-brain barrier (BBB) shuttle platform designed to carry cargo such as antibodies into the CNS; SNP234, a next-generation anti-amyloid antibody selective for aggregated beta-amyloid species over monomeric forms; SNP203, an anti-SORT1 antibody intended to raise extracellular progranulin levels by blocking the PGRN-SORT1 interaction, relevant to GRN-associated frontotemporal dementia and Alzheimer's disease; SNP622, an antisense oligonucleotide that reduces APOE expression in human brain cells, targeting the APOE4 Alzheimer's risk allele; and SNP614, a program directed at LRRK2, a GTPase/kinase whose gene mutations are linked to Parkinson's disease. Company materials also reference programs addressing Lp-PLA2 (lipoprotein-associated phospholipase A2).
The company describes a research model combining in-house discovery and development with collaborations with external scientists and institutions, and an approach that integrates a patient's underlying genetics, health history and environmental factors with imaging, biomarkers and other diagnostic tools to guide targeted, disease-modifying therapy development.
Founding story
Sources state the company was founded in 2020 by Min Li, PhD, who serves as Founder and CEO. No further detail on the founding circumstances is provided in the available sources.
Business model
SciNeuro is a therapeutics developer that discovers and advances proprietary CNS drug candidates and platform technology, funding operations through venture equity financing and non-dilutive grants, and monetizing assets through out-licensing and collaboration agreements with large pharmaceutical partners. The January 2026 Novartis agreement illustrates this model: an exclusive worldwide license to an amyloid-beta antibody program in exchange for an upfront payment, research funding, development/regulatory/commercial milestones and tiered royalties, with the partner leading later-stage development and commercialization.
Non-product revenue from partnership economics: upfront payments, research funding, development, regulatory and commercial milestone payments, and tiered royalties, as structured in the Novartis agreement.
Traction
Founded 2020; described as clinical-stage with a portfolio spanning discovery to clinical development. Disclosed traction includes $53 million in equity financing (December 2025), a $5 million Michael J. Fox Foundation research grant for the LRRK2 program, and a January 2026 worldwide license and collaboration with Novartis carrying a $165 million upfront payment plus up to $1.5 billion in potential milestones and tiered royalties.
Latest developments
December 4, 2025: announced completion of $53 million equity financing led by LAV and ARCH Venture Partners and appointed Hogan Wan as CFO. The company also disclosed a recent $5 million non-dilutive grant from The Michael J. Fox Foundation for Parkinson's Research supporting SNP614. January 12, 2026: announced an exclusive worldwide licensing and collaboration agreement with Novartis Pharma AG for its de novo amyloid-beta targeted antibody program incorporating its BBB shuttle technology, with a $165 million upfront payment, eligibility for research funding and up to $1.5 billion in development, regulatory and commercial milestones plus tiered royalties; the transaction was expected to close in the first half of 2026 subject to Hart-Scott-Rodino waiting period expiration and other customary conditions.
▸Full profile — market position, technology, go-to-market, geography, history, risks & controversies
Market position
SciNeuro is positioned as an emerging CNS-focused biotech backed by ARCH Venture Partners and Lilly Asia Ventures, two firms active in neuroscience investing. Commentary characterizes neurodegeneration as a high-attrition, historically difficult development area, with capital returning selectively to companies grounded in validated human genetics and mechanistic biology. The Novartis license for its anti-amyloid antibody program provides external validation of its BBB shuttle-enabled antibody approach.
The company cites a modular BBB shuttle platform it describes as best-in-class in efficiency and pharmacokinetics and applicable across modalities, combined with programs claiming advantages over benchmark or competitor molecules (e.g., SNP622 in vivo efficacy versus a benchmark ASO; SNP203 potency, pharmacokinetics, dosing and delivery versus competitor anti-SORT1 molecules; SNP234 selectivity for aggregated over monomeric amyloid). It also emphasizes an integrated patient-centric approach combining genetics, health history, environmental factors, imaging and biomarkers.
Technology
The company's core enabling technology is a modular blood-brain barrier shuttle platform (SNP837) that, when combined with a therapeutic cargo such as an antibody, is intended to increase CNS concentration and biodistribution to deep brain regions, and which the company states is applicable across multiple therapeutic modalities. Around this platform it develops antibodies (SNP234 anti-amyloid; SNP203 anti-SORT1), antisense oligonucleotides (SNP622 targeting APOE), and small-molecule/protein-directed programs including LRRK2 (SNP614) and Lp-PLA2 pathways.
Go-to-market
SciNeuro advances programs internally from discovery through early development and then partners with larger pharmaceutical companies for late-stage development and worldwide commercialization, as with Novartis leading development and commercialization of the licensed amyloid-beta antibody program after a joint early-development phase.
Patients with neurodegenerative and other CNS diseases, including Alzheimer's disease, Parkinson's disease and frontotemporal dementia; near-term commercial counterparties are large pharmaceutical companies that license and commercialize its programs.
Geography
Headquartered in Rockville, Maryland, USA, within Maryland's life sciences ecosystem; the company describes global reach and collaborations with scientists worldwide, and its investor base includes China-based LAV/Lilly Asia Ventures. One secondary source characterizes it as a China-linked company.
History
SciNeuro was founded in 2020 and is headquartered in Rockville, Maryland. In December 2025 it announced the completion of $53 million in equity financing led by LAV (Lilly Asia Ventures) and ARCH Venture Partners with participation from new and existing investors, alongside the appointment of Hogan Wan as Chief Financial Officer. The company also received a $5 million non-dilutive research grant from The Michael J. Fox Foundation for Parkinson's Research under the foundation's Therapeutics Pipeline Program to accelerate development of its LRRK2 program, SNP614. In January 2026 SciNeuro announced a worldwide licensing and collaboration agreement with Novartis Pharma AG for its amyloid-beta targeted antibody program.
Risks & controversies
The Novartis transaction had not closed as of announcement and remains subject to antitrust clearance under the Hart-Scott-Rodino Act and other customary conditions. Sources note that CNS and neurodegeneration drug development has notably lower success rates than other therapeutic areas and long development timelines with high attrition. Two of the disclosed executive roles (CMO and CBO) are held on an interim basis. Comparative claims about pipeline candidates are company statements not independently verified in the sources.
Compiled by commissioned research from 8 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Competitors · 1
by search overlapCompanies competing with SciNeuro Pharmaceuticals for the same Google search keywords, organic and paid, via search-intersection analysis.
Timeline · 4
launches, deals, and filingsSciNeuro granted Novartis Pharma AG an exclusive worldwide license to develop its de novo amyloid-beta targeted antibody program incorporating SciNeuro's proprietary blood-brain barrier shuttle technology for Alzheimer's disease. The parties will collaborate during early development, with Novartis leading subsequent development and commercialization worldwide. Terms include a $165 million upfront payment, eligibility for research funding, up to $1.5 billion in development, regulatory and commercial milestones, and tiered royalties. Closing was expected in the first half of 2026, subject to Hart-Scott-Rodino clearance and other customary conditions.
$165M source ↗
SciNeuro announced completion of a total of $53 million in equity financing led by LAV (Lilly Asia Ventures) and ARCH Venture Partners with participation from new and existing investors, to advance its pipeline targeting Lp-PLA2, beta amyloid and LRRK2 and other CNS discovery work.
$53M source ↗
SciNeuro appointed Hogan Wan as CFO, responsible for corporate financial management, strategy and operations. Wan previously was Head of Investor Relations and Strategy at Ascentage Pharma and held roles at Goldman Sachs, J.P. Morgan, UBS Investment Bank and CBC Group.
SciNeuro received $5 million in non-dilutive funding from The Michael J. Fox Foundation for Parkinson's Research, as part of MJFF's Therapeutics Pipeline Program, to accelerate development of its LRRK2 therapeutic SNP614.
$5M source ↗
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
In the news
▸Research sources · 8
primary sources listed
- SciNeuro Pharmaceuticalsscineuro.com · web
8 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does SciNeuro Pharmaceuticals do?
- Clinical-stage biotech founded in 2020 developing disease-modifying therapies for Alzheimer's, Parkinson's and other CNS disorders.
- Who are SciNeuro Pharmaceuticals's investors?
- SciNeuro Pharmaceuticals's investors include ARCH Venture Partners.
- Where is SciNeuro Pharmaceuticals headquartered?
- SciNeuro Pharmaceuticals is headquartered in Rockville, US.